The in vitro Effect of Doxorubicine-G2-FA Treatment on Breast Cancer Copyright

Document Type: Clinical Pathology


1 1Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

2 Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

3 Pasteur Institute of Iran, Research and Production Complex, Department of Research and Development

4 3Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

5 4Department of Pathobiology, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran


To achieve delivery of a drug to tumors, folic acid (FA) was used as a targeting ligand to
change nanocarriers. Since the folate receptor has more expression in several tumor types such as breast cancer.
The present study aimed to evaluate the effect of Doxorubicine-G2-FA (Dox- G2-FA) with
in vitro assays. The abbreviation of G2 represents the second generation of dendrimer synthesis.
For this purpose, Dox-G2-FA was synthesized and mass spectroscopy was used to confirm the
synthesized component. Also, MTT assay, flow cytometry, and gene expression assay by real-time PCR were
used to evaluate cell viability, apoptosis, and necrosis.
In this study, the effect of Dox and Dox-G2-FA on the expression of Bax, Bcl2 genes showed
that there was a significant decrease in the expression of the Bcl2 gene in the Dox-G2-FA group compared to
Dox and control groups(
P<0.05). Also, the results of flow-cytometry showed that apoptosis in the presence of
Dox-G2-FA was greater than in the Dox group (
Therefore, it seems that the effect of Dox-G2-FA on apoptosis is better than the effect of
Dox usage alone.


Article Title [Persian]

تاثیر in vitroدوکسوروبیسین FA-G2- بر سرطان سینه

Authors [Persian]

  • حامد منصور لکورج 1
  • زهره خاکی 2
  • مسعود قربانی 3
  • مهدی شفیعی اردستانی 4
  • امید دزفولیان 5
1 بخش کلینیکال پاتولوژی، دانشکده دامپزشکی، دانشگاه تهران، تهران، ایران
2 بخش کلینیکال پاتولوژی، دانشکده دامپزشکی، دانشگاه تهران، تهران، ایران
3 بخش تحقیق و توسعه، انستیتو پاستور ایران، مجتمع تحقیق و توسعه، تهران، ایران
4 بخش رادیودارو، دانشکده داروسازی، دانشگاه علوم پزشکی تهران، تهران، ایران
5 گروه پاتوبیولوژی، دانشکده دامپزشکی، دانشگاه لرستان، خرم آباد، ایران
Abstract [Persian]

زمینه مطالعه:
برای رسیدن دارو به تومورها، از اسید فولیک ) FA ( به عنوان لیگاند هدفمند جهت تغییر حاملین نانو استفاده می شود. زیرا که گیرنده فولات
به میزان زیادی در چندین نوع تومور همچون سرطان سینه بیان می شود.
هدف مطالعه حاضر، ارزیابى in vitro اثر دوکسوروبیسین FA-Dox- G2)-FA-G2 ) بر روى سرطان سینه مى باشد و اختصار G2
نسل دوم سنتز دندریمر را نشان مى دهد.
روش کار:
به همین منظور، FA-Dox-G2 تولید و از طیف سنجى جرمى براى تایید مؤلفه هاى سنتزى استفاده شد. همچنین آزمایش
، فلوسایتومترى و تعیین بیان ژن جهت ارزیابى زنده مانى سلول، آپوپتوز و نکروز نیز انجام شد.
در این مطالعه، اثر Dox و FA-Dox-G2 در بیان ژن هاى Bax و Bcl2 نشان داد که در بیان ژن Bcl2 در گروه FA-Dox-G2 در
مقایسه با گروه هاى کنترل و
Dox کاهش معنى دارى وجود دارد ( 05 / P>0 ). همچنین، نتایج فلوسایتومترى نشان داد که نرخ آپوپتوز در حضور
-Dox-G2 بیشتر از گروه Dox مى باشد ( 05 / .(P>0
نتیجه گیری نهایی:
براساس نتایج مطالعه حاضر ، اثر FA-Dox-G2 بر آپوپتوز ، بهتر از اثر Dox به تنهایى مى باشد.

Keywords [Persian]

  • دوکسوروبیسین FA-G2-
  • سرطان سینه
  • آپپتوزیس
  • Bax
  • Bcl2


Breast Cancer is considered one of the most devastating diseases with a high mortality rate among the female population (AbuHam- mad and Zihlif, 2013). Therapeutic options of breast cancer are dependent on specific biological features of tumors. In low grade and estrogen-receptor-positive, hormone therapy is a good option for the treatment of cancer. Chemotherapy is another technique for the treatment of cancer and serves as the preferred treatment. Dox is the current ther- apy for the treatment of breast cancer. The main function of Dox is the intercalation of DNA, the prevention of topoisomerase II, and the formation of free radicals (Lovitt et al., 2018). A key mechanism in the answer of cancer cells  to  chemotherapeutic  drugs is their apoptotic way of activation. Also, substantial toxic effects, side effects,  and  fast degradation have limited clinical use of chemotherapeutic drugs (Le et al., 2017). One study reported that the most harmful side effect of doxorubicine was cumulative dose-dependent cardiotoxicity. To minimize these side effects, and to limit drug disper- sion into healthy tissues, chemotherapeutic drugs, including doxorubicine can be used with drug carriers (Tomankova et al., 2015). Nano-materials are considered noteworthy pharmacological carriers for drug delivery and cancer therapy. Targeted nano-materi- als selectively affect cancer cells via binding to them, with minor effects on healthy cells (Samad et al., 2009). Among several  types of nano-materials, dendrimers are extensive- ly ideal carriers (Senapati et al., 2018), be- cause they are radially symmetrical, globular and Nanodimensionally compact structures with tree-like branches or arms (Singh et al., 2019). To achieve drug delivery to tumors, folic acid (FA) was used as a targeting ligand


to change nanocarriers (Wang et al., 2015, Qin et al., 2013, Duan et al., 2012, Zwicke  et al., 2012). Folic acid  plays  a major role in the synthesis of DNA and RNA as well  as cellular growth and metabolism. Uptake of folate to a cell is mediated through cell membrane folate receptors which are consid- ered heterogeneous proteins. Furthermore, folate receptor-alpha is a glycosylphosphati- dylinositol (Sheikh et al., 2016) that has low expression in normal cells. However, it is over-expressed in several tumor types such as breast cancer and gynecological cancers of epithelial origin (Samad et al., 2009, Kalli et al., 2008). Studies have demonstrated that diverse folate conjugated nanomaterials as gold nanoparticles are highly important in targeted cancer therapy. Gold nanoparticles have been recognized as hopeful candidates for novel cancer therapy, owing to biocom- patibility,  chemo-physical  stability,  and easy functionalization (Samad et al., 2009). Therefore, this paper intends to evaluate the effect of Dox-G2-FA in vitro considering cytotoxicity, apoptosis, and gene expression assay on the MCF-7 breast cancer cell line.

Materials and methods

Synthesis  of DOX-G2-FA

Figure 1-A shows the synthesis of G2 dendrimer. Polyethylene glycol diacid was dissolved in Dimethyl sulfoxide  (DMSO)  by adding N, N'-dicyclohexylcarbodiimide (DCC) (0.75 gr, 0.0036 mol) to the solution and stirring for 30 min at room temperature, and carboxyl groups were activated for con- jugation. G1 dendrimer was obtained by adding citric acid (0.71 gr, 0.0036 mol) to  the solution and stirred for 1 h at room tem- perature.  To   the  obtained  product (2.25 gr,

0.01 mol) DCC and 5 mL DMSO were add-




ed and the reaction was carried out under the same-mentioned conditions for 15 min. Fi- nally, citric acid (2.1 gr, 0.01 mol) was add-  ed and the mixture  was  stirred  for  1  week at room temperature. After that, the G2 den- drimer was filtered twice and purified using a Sephadex G-50 fine column (GE Healthcare Life Sciences, UK) and dialysis (dialysis bag 500–1000 Da cut-off, Spectrumlab, USA) against double deionized water (1 × 1 L for 2 days). The purified product was freeze-dried (LyoTrap plus, LTE Scientific Ltd, Oldham,

UK) and stored at −20 °C for future studies. To prepare a dendrimer-folate conjugate, 0.05 gr of dendrimer was dissolved in DMSO (15 ml) and mixed with DCC (2.25 gr, 0.01 μmol). After stirring for 30 min, folic acid (0.001 gr,

2.26 mol) was added and stirred continuously at room temperature for 4 days to react com- pletely. The final conjugate was purified us- ing a Sephadex G-50 fine column and dialysis (Namazi and Adeli, 2005; Alavidjeh et al., 2010). Figure 1-B shows the conjugation of folic acid to G2 dendrimer.























Figure 1. (A) Synthesis of G2 dendrimer; (B) Conjugation of folic acid to G2 dendrimer




Dox-G2-FA was obtained by mixing and incubating Dox (Santa Cruz Biotechnolo- gy Inc., Texas, USA) (5 mg, 9.2μmol) and 10 mg G2-FA for one day. Finally, excess Dox was removed by dialysis and the final product was centrifuged (13000rpm, 4 °C, 30 min) to remove any impurity. Therefore, an anionic linear  globular  dendrimer  that is biocompatible  and  biodegradable  (Le  et al., 2017), conjugated to folic acid, and then doxorubicin, which acts nonspecifical- ly against cancer cells, is loaded with this compound and the ultimately intelligent an- ti-cancer system was designed.

To evaluate and calculate the loading effi- ciency, a calibration curve was obtained by recording the absorbance value of different concentrations of the Dox solution at 480 nm wavelength firstly. Then, the absorbance value from the unloaded drug solved in the water (during dialysis) was used to calculate loading efficiency (LE) using the equation below (Khosravian et al., 2016):

obtained from Pasteur Institute (Tehran, Iran) and were cultured in a low glucose Dulbec- co's modified Eagle's medium (DMEM) con- taining 2 mM glutamine, 0.01 mg/ml insulin and 1% penicillin/streptomycin mix, supple- mented with 10 % fetal calf serum (FCS)and need to be incubated at 37 °C in an atmo- sphere of 5% CO2(Mehrizi et al., 2018).

Cytotoxicity analysis (MTT assay)

MTT assay is a rapid colorimetric test to determine the cell viability and cytotoxicity for screening new drugs (Mosmann, 1983). In this assay, NAD(P)H-dependent cellular oxidoreductase enzyme converts the  yel- low tetrazolium MTT 3-(4,5-dimethyl thi- azolyl-2)-2,5-diphenyltetrazolium bromide into insoluble (E,Z)-5-(4,5-dimethylth- iazol-2-yl)-1,3-diphenylformazan(for- mazan). The insoluble purple formazan can be dissolved with DMSO, and purple color intensity indicates the cell viability. In the current study, the MTT assay was performed as described by Bahuguma et al (2017). In brief, MCF-7 cells were plated in 96- well


LE% =

Added drug - unloaded drug × 100

Added drug

flat-bottom plates at a density of 1 x 104 cells/well for 24 h at 37 ◦C with 5% CO2  for stabilization. Then, after 24 h, the culture


The morphology, mean size, and zeta po- tential of the G2-FA conjugates are deter- mined by atomic force microscopy (AFM) (ENTEGRA AFMNT–MDT, Russia) and dy- namic light scattering (DLS)(Zetasizer Nano ZS; Malvern Instruments, Malvern, UK). The characterization of G2-FA was determined by mass spectroscopy (LC/MS). LC/MS analy- ses were provided by Triple Quadrupole LC/ MS (Agilent 6410, USA). Fluorescence spec- troscopy was used to investigate drug loading in dendrimer using a fluorescence spectro- photometer (Perkin Elmer, LS 45, USA).

Cell culture

MCF-7 human breast cancer cells were

medium was removed and fresh medium was added. Afterward, the cells were treated with Dox and Dox-G2-FA independently of each other at different concentrations (5, 10, 50, and 100µg/ml). A negative control (untreated cells) was also used. Again, after 24 and 48 h treatment, the culture medium was replaced. Then, 10 µl of MTT (Sigma, Germany) was added and after 4 h at 37 °C in a CO2 incuba- tor, the medium was removed. The formazan crystals were solubilized by adding 50 µL of DMSO and allowed to be incubated for 30 min at 37 °C in a CO2 incubator. Ultimately, the color intensity (absorbance) was record- ed at 540 nm using the ELISA plate reader




(ELX 808, Biotek, USA). The mean absor- bance of each reaction was converted to cell viability (%) through the following equation: (Mean absorbance treatment/mean absor-

bance control) ×100

A blocking test was performed to deter- mine the selectivity and importance of folate in binding to cancerous tissue. For this pur- pose, different values of folic acid (0.5, 1, 5, and 10 µg/ml) were added to the cell line, and then the same MTT assay was examined.

Evaluation of apoptosis and necrosis by the flow- cytometry technique

Briefly, the principle of Annexin V- Fluores- cein isothiocyanate (FITC) staining assay for the flow- cytometry technique (Cy Flow Space, Partec, Germany) is presented as follows.

Viable cells maintain an asymmetric dis- tribution of different phospholipids between the inner and outer leaflets of the plasma membrane. Phosphatidylserine (PS) is locat- ed in the inner leaflet of normal cells. Apop- totic cells exposed PS on the outer leaflet of the plasma membrane, while the membrane integrity remains unchallenged in the early phases of apoptosis. However, the translo- cated PS can be detected by staining with a FITC conjugate of Annexin  V.  Annexin  V is a calcium-dependent phospholipid-bind- ing protein that specifically binds to PS. Changes in PS asymmetry can be detected by Annexin V–FITC staining for the flow- cytometry  method  before  the  occurrence of morphological changes associated with apoptosis and before a loss of membrane integrity. To differentiate between apoptotic and necrotic cells, a membrane-impermeable DNA stain, like propidium iodide (PI), can be added concurrently to the cell suspension (Van Engeland et al., 1998).

Thus, 4 labeling patterns in the mentioned assay may be observed on 4 regions or quar-

ters: Damaged cells during the isolation procedure (Q1) - Annexin V negative and PI-positive; Apoptotic cells (Q2) - Annexin V positive and PI negative; Vital cells (Q3)

- negative for both Annexin V and PI; Ne- crotic cells (Q4) - positive for both Annexin V and PI.

In this technique, we placed 5×104 cells/ ml in each plate, and Dox and Dox-G2-FA were added to each plate. The cells were separated from the plate after washing with phosphate buffer solution (PBS) and trypsin enzyme and were put through centrifuges. The cells were washed with a buffer solution and centrifuged to be isolated. FITC solution (Sigma, USA) was incubated with Annexin (Sigma, USA) (5 μl) for 15 min at room tem- perature in a dark environment. PI (Sigma, USA) (5 μl) was added, which was attached to the DNA in necrotic cells. Thus, for this purpose, the measurement of induced apop- tosis by Dox and Dox-G2-FA was assessed by a FACScan flow cytometer (BD FACS- Calibur, USA).

Gene expression assay by real-time PCR RNA was extracted from the breast can- cer cell line (MCF-7) according to the man- ufacturer’s instructions (Qiagen, USA). The final RNA was detected by the spectroscopy method. Primers were designed by the com- puter program Primer Express. Real-time PCR includes 0.35 ml cDNA template and 50–900 nM of oligonucleotide primer, 1X SYBR RT-PCR buffer, 0.2 mM each of dATP, dCTP,  dGTP,  3 mM MgCl2, 0.4 mM dUTP,

0.005 U Ampli Taq Gold, 0.002 U AmpEr- ase UNGerase enzyme, primer and forward primer in 10 ml volume. PCR reactions were performed following thermal cycling profile: 95 °C for 10 min, followed by 40 steps of 95

°C for 30 s and 58 °C for 1 min and 72 °C for 1 min. After 40 cycles, the samples were run




for the dissociation protocol. Then, the PCR products were run on a 2% agarose gel to de- tect the presence of a band with the expected

size (Hashempour Alamdari et al., 2017).

Forward and reverse primer used in the current study are listed below:


















Data analysis

Statistical data analysis was conducted  by one-way ANOVA. All the analyses were conducted by SAS (SAS Institute Inc., Cary, NC, USA). Data are presented as mean ± SEM. Differences with P-value<0.05 were considered significant.


The size of the G2-dendrimer and the G2- FA were 80 nm and 140 nm respectively. Besides, the results of zeta potential analy- sis indicated that G2-FA(-52 mV) was neg- ative compared to G2-dendrimer (-22 mV) confirming the conjugation folic acid to the G2-dendrimer.

The AFM analysis results showed that the G2-dendrimer has a semi-spherical shape with an average size of 70 nm (Figure 2-A), while the G2-FA had a stretched shape and a size of 125 nm (Figure 2-B). Furthermore, these results are in good agreement with the DLS analysis results.

The results of the Dox loading showed that in the first 14 h of the study, 58% of the drug was loaded into the dendrimer. After that, there was no significant loading (Fig-

ure 2 – C). Also, it was illustrated that the drug was released slowly, and the highest percentage of release occurred at the acidic pH (81%; pH= 5.5) (Figure 2- D).

The results of the MTT assay  showed that the viability of the cells after treatment with different concentrations of Dox-G2- FA (except 5 µg/ml) in comparison to Dox was significantly decreased (P<0.05) (Fig- ure 3-A). Also, the results of the MTT assay indicated that the viability of the cells after treatment with 50 and 100 µg/ml of Dox- G2-FA compared to the Dox group was sig- nificantly decreased(in the presence of the blocking test) (P<0.05)(Figure.3-B).

As Figure 3-C showed, there is a sig- nificant decrease in the Dox-G2-FA group compared to the Dox and the control groups in terms of the Bcl2 gene (P<0.05).

As Figure 4 shows, 95.05 % of the cells existed in normal status in the control group. In the Dox group, 52.16 % of the cells showed apoptosis and 30.88 % of cells ne- crosis in the presence of Dox; While 61.69

% of cells showed apoptosis, and 24.11 % of the cells necrosis in the presence of Dox- G2-FA (P<0.05).





Figure 2. (A)- (a)2D, (b)3D and (c) size distribution AFM micrograph of G2-dendrimer (B)- (a) 2D, (b)3D and (c) size distribution AFM micrograph of G2-FA (C)- Drug loading profile; (D) Cumulative release curve



 Figure 3. (A)- Results of the MTT assay on MCF-7 cells with different concentrations of Dox and Dox-G2-FA;(B)- Results of the MTT assay on MCF-7 cells with different concentrations of Dox and Dox-G2-FA (in the presence of the blocking test); (C)-Bax and Bcl2 gene expression of drug and nano-drug in MCF-7 cell line(*=P<0.05, **= P<0.01).




Figure 4. Flow- cytometry results - (a) control, (b) Dox and (c) Dox-G2-FA groups




The use of chemotherapeutic drugs is one of the several ways to treat cancer and tu- mors. These drugs can also be applied to ra- diation or surgery methods. However, they may have undesirable or unwanted effects (Senapati et al., 2018).

Dox is used to treat various cancers. More- over, it is one of the chemotherapy agents used in the treatment of breast cancer. It acts by blocking the replication and transcription processes (Lovitt et al., 2018). Although an acceptable outcome has been seen in the che- motherapy of some cancers, they also show undesirable toxicity and severe complication (Le et al., 2017). The targeted drug delivery using polymer nanoparticles with their unique characteristics such as biocompatibility, mon- odispersity index, and three-dimensional globular shapes can overcome these problems (Lovitt et al., 2018). In the current study, we synthesized G2-Folic acid having the ability  to carry Dox for targeted release (delivery) to the breast cancer cell. The amounts of drug loading and release from this nano-carrier were 58% and 81% respectively. Atomic force microscopy, mass spectroscopy, fluorescent spectroscopy, dynamic light scattering, and zeta potential, confirmed the successful syn- thesis and drug loading. In this carrier, folic acid conjugated via covalent binding. Target-

ed delivery of anticancer drugs may be more advantageous than chemotherapy (Mehrizi et al., 2018). Some polymers such as polyeth- ylene glycol and chitosan have been used for tumor-targeted delivery (Duan et al., 2012). Moreover, drug carriers may be modified with a ligand to increase their ability (Yoo et al., 2019). In the current study, we synthesized G2-Dox and confirmed it by mass spectros- copy, then attached it to folic acid. Folic acid as a group of water-soluble vitamin B is one of the main elements involved in DNA syn- thesis or cell division (Yilmaz and Walhout, 2014). Folic acid transports drugs to cancer cells via folate receptors on the cell surface. Parveen et al (2010) reported that the folate receptor was over-expressed in many cancers and emerged as a targeting ligand for selective delivery. Compared to some commonly used dendrimers like Poly amidoamine (PAMAM) having a positive charge, the synthesized na- no-carriers are  more  biocompatible  owing  to its negative charge. This feature led to the use of second-generation dendrimer for drug delivery. The positive charge of PAMAM dendrimer was instigated to use fourth and fifth-generation which leads to increase in the cost and time of synthesis and low drug-load- ing efficiency (Javani et al., 2017, Luong et al., 2016, Sowinska and Urbanczyk-Lipkow- ska, 2014, Alavidjeh et al., 2010).




Flow cytometer analysis showed that apoptosis and necrosis were observed in 52.16% and 30.88% of cells in the presence of doxorubicin. In the presence of Dox-G2- FA, 61.6% and 24.11% of the cells showed apoptosis and necrosis, respectively. It seems that Dox-G2-FA causes more apoptosis than Dox. The mechanism of the action of doxo- rubicin on apoptosis is not completely clear. Probably, it causes loss of the mitochondrial membrane potential and activates the intrin- sic mitochondrial/caspase-9 way(Debatin, 1997). Compared to the result of Myc et al (2010) (Myc et al. 2010), the synthesized particle has shown an acceptable and better result that can be derived from the small size, the low-generation, ability to load the wiz- ard, the adaptability of the structure. Also, compared with the control and Dox groups, reduction of the antiapoptotic Bcl-2 expres- sion could be attributed to an increased sen- sitivity of the MCF-7 cells to induce apop- tosis when exposed to synthesis structure (Javani et al., 2017), indeed the reduction of Bcl2 can restore the apoptotic process in tu- mor cells (Czabotar et al., 2014).

According to the present study results, there was a significant decrease in the ex- pression of the Bcl2 gene in the Dox-G2-FA group compared to Dox  group.  Moreover, in flowcytometry, apoptosis in the presence of Dox-G2-FA was greater than in the Dox group. Therefore, it seems that the effect of Dox-G2-FA on apoptosis is better than free Dox. In this regard, more investigations are needed on the effect of Dox-G2-FA on dif- ferent cell lines as well as in vivo assay.


The authors wish to thank the staff of Tehran University of Medical Sciences who helped us to do this research.


Conflict of Interest

The authors declared that there is no con- flict of interest.

AbuHammad, S., Zihlif, M. (2013) Gene expression

alterations in doxorubicin resistant MCF7

breast cancer cell line. Genomics, 101,213–220. 10.1016/j. ygeno 2012.11.009.




Alavidjeh, M. S., Haririan, I., Khorramizadeh,

M.R., Ghane, Z.Z., Ardestani, M.S., Namazi, H.

(2010) Anionic linear-globular dendrimers: biocompatible

hybrid materials with potential uses

in nanomedicine. J Mater Sci Mater Med., 21,



https:// doi. org/10.1007/s10856-



. PMID: 20082119

Bahuguna, A., Khan, I., Bajpai, V.K., Kang,

S.C.(2017) MTT assay to evaluate the cytotoxic

potential of a drug. Bangladesh J Pharmacol.,



https:// 3329/ bjp.




Czabotar, P.E., Lessene, G., Strasser, A., Adams,J.M.

(2014) Control of apoptosis by the BCL-2 protein

family: implications for physiology and therapy.

Nat Rev Mol Cell Biol., 15(1), 49-63.



doi. org/10.1038/nrm3722


. PMID: 24355989

Debatin, K.M. (1997) Cytotoxic drugs, programmed

cell death, and the immune system: defining new

roles in an old play. J Natl Cancer Inst., 89,750–



https:// doi. Org/10. 1093 /jnci/89.11.750.




Duan, J., Liu, M., Zhang, Y., Zhao, J., Pan, Y., and

Yang, X. (2012) Folate-decorated chitosan/doxorubicin

poly (butyl) cyanoacrylate nanoparticles

for tumor-targeted drug delivery. Journal of

Nanoparticle Research, 14(4), 761.

Nanopart Res., 14,761-770.


https:// doi.




Hashempour Alamdari, N., Alaei-irami, M. ,Shandiz,

S.A.S., Hejazinia, H.,Rasouli, R.,Saffari, M.,

Ebrahimi, S.E.S.,Assadi, A., Shafiee Ardestani,

M. (2017) Gd3+-Asparagine-Anionic Linear

Globular Dendrimer Second-Generation G2 Com



vitro effect of Dox-G2-FA on Breast Cancer Hamed Mansoor Lakooraj et al.



Iran J Vet Med., Vol 14, No 2 (Spring 2020)

plexes: Novel Nanobiohybrid Theranostics. Contrast

Media Mol Imaging, 2017, 1-19.


https:// 2017/ 3625729



Javani, B., Fattah, S., Saffari, M,. Shafiee Ardestani,

M.(2017) Gd3+-DTPA-bis (N-methylamine)-

Dendrimer significantly alters Bax/Bcl2

gene expression levels in MCF-7 cancer cells.

Biomed Res., 28, 2411-2426.

Kalli, K.R., Oberg, A.l., Keeney, G.L.,Christianson,

T.J., Low, P.S., Knutson, K.L.,

Hartmann, L.C. (2008) Folate receptor alpha as a tumor

target in epithelial ovarian cancer. Gynecol

Oncol., 108, 619-26.


https:// doi. Org/10.1016.

/j. ygyno 2007.11.020.


PMID: 18222534

Khosravian, P., Ardestani, M.S., Khoobi M., Ostad,

S.N., Dorkoosh, F.A., Javar, H.A.,Amanlou,

M.(2016) Mesoporous silica nanoparticles functionalized

with folic acid/methionine for active

targeted delivery of docetaxel. Onco Targets

Ther., 9, 7315-7330.


https:// doi. org/10.2147/



. PMID: 27980423

Le ,V.M., Tran Nho, T.D., Trieu Ly H., Vo, T.S.,

Dung Nguyen, H., Thu Huong Phung, T.,Zou, A.,

Liu, J. (2017) Enhanced anticancer efficacy and

tumor targeting through folate- PEG modified

nanoliposome loaded with 5-fluorouracil. Adv

Nat Sci: Nanosci Nanotechnol., 8,1-7.



doi. org/10.1088/2043-6254/aa5982



Lovitt, C.J., Shelper, T.B., Avery, V.M.(2018) Doxorubicin

resistance in breast cancer cells is mediated

by extracellular matrix proteins. BMC Cancer,

18, 41.


https:// doi. org/ 10. 1186/s12885-017-



. PMID: 29304770

Luong, D., Kesharwani, P., Deshmukh, R., Mohd

Amin, M.C.I.,Gupta, U., Greish ,K., Iyer,

A.K. (2016) PEGylated PAMAM dendrimers: Enhancing

efficacy and mitigating toxicity for effective

anticancer drug and gene delivery. Acta

Biomater., 43,14-29.


https:// doi. Org/10.1016



. PMID: 27422195

Mehrizi, T. Z., Ardestani, M.S., Hoseini ,M.H.M.,

Khamesipour, A.,Mosaffa, N.,Ramezani, A.

(2018) Novel nanosized chitosan-betulinic acid

against resistant leishmania major and first clinical

observation of such parasite in Kidney. Scientific

Reports, 8, 11759.


https://doi. org/10.1038/




Mosmann, T. (1983) Rapid colorimetric assay for

cellular growth and survival: application to proliferation

and cytotoxicity assays. J Immunol Methods,

65, 55-63. h


ttps:// /10. 1016/0022-



. PMID: 6606682

Myc, A., Kukowska-Latallo, J., Cao, P., Swanson,

B., Battista, J., Dunham, T., Baker, Jr. (2010)

Targeting the efficacy of a dendrimer-based nanotherapeutic

in heterogeneous xenograft tumors

in vivo. Anticancer Drugs, 21, 1-15.



doi. org/10.1097/CAD. 0b013e328334560f






Namazi, H., Adeli, M. (2005) Dendrimers of citric

acid and poly (ethylene glycol) as the new

drug-delivery agents. Biomaterials, 26, 1175-



https: // biomaterials.



PMID: 15451637

Parveen, S., Sahoo,S.K.(2010) Evaluation of cytotoxicity

and mechanism of apoptosis of doxorubicin

using folate-decorated chitosan nanoparticles

for targeted delivery to retinoblastoma.

Cancer Nano.,1,47–62.



.PMID: 26069479

Qin, X.C., Guo, Z.Y., Liu, Z.M., Zhang, W., Wan,

M.M., Yang, B.W. (2013) Folic acid conjugatedgraphene

oxide for cancer targeted chemo-photothermal

therapy. J Photochem Photobiol B,



https:// doi. org/10.1016/j.photobiol.



. PMID: 23357205

Samad, A., Alam, M.I., Saxena, K.(2009) Dendrimers:

a class of polymers in the nanotechnology

for the delivery of active pharmaceuticals.

Curr Pharm Des,15, 2958-69.


https:// doi.





Senapati, S., Mahanta A.K., Kumar, S., Mati, P.

(2018) Controlled drug delivery vehicles for cancer

treatment and their performance. Signal Transduct

Target Ther., 3,7.




Sheikh, U.N., Cohen, C., Siddiqui, M.T. (2016)

Utility of folate receptor alpha immunohistochemistry

in cytology specimens of metastatic

breast carcinoma, metastatic serous carcinoma of

Müllerian origin, and primary lung adenocarcino



Mansoor Lakooraj et al.


Iranian Journal of Veterinary Medicine

Iran J Vet Med., Vol 14, No 2 (Spring 2020)

ma. Diagn Cytopathol., 44, 369-376.


https:// doi.



PMID: 26875861.

Singh, A.P., Biswas, A., Shukla, A. , Maiti, P. (2019)

Targeted therapy in chronic diseases drug delivery

vehicles. Signal Transduct Target Ther., 4, 33.

https:// doi. org/10.1038/s41392-019-0063-3



Sowinska, M., Urbanczyk-Lipkowska, Z. (2014)

Advances in the chemistry of dendrimers. New J

Chem ., 38,2168-2203.


https:// doi. org/10.1039/




Tomankova, K., Polakova, K., Pizova, K., Binder, S.,

Havrdova, M., Kolarova ,M., Kriegova,

E., Zapletalova, J., Malina, L., Horakova ,J., Malohlava,

J., Kolokithas- Ntoukas, A., Bakandritsos, A.,

Kolarova , H., Zboril, R.(2015) In vitro cytotoxicity

analysis of doxorubicin-loaded/ superparamagnetic

iron oxide colloidal nanoassemblies

on MCF7 and NIH3T3 cell lines. Int J Nanomed

, 10,949-961.


https:// doi. org/ 10.2147/IJN.



. PMID: 25673990

Van Engeland, M. ,Nieland, L.J.,Ramaekers, F.C.,

Schutte, B., Reutelingsperger, C.P. (1998) Annexin

V- affinity assay:A review on an apoptosis

detection system based on phosphatidylserine

exposure. Cytometry ,31,1-9.

10.1002/ (sici) 1097-0320(19980101) 31: 1<:

aid- cyto1>; 2-r


. PMID:9450519

Wang, Y., Li, P., Chen, L., Gao, W., Zeng, F., Kong,

L.X. (2015) Targeted delivery of 5-fluorouracil to

HT-29 cells using high efficient folic acid-conjugated

nanoparticles. Drug Deliv., 22, 191-198.

https:// 10.3109/10717544.2013.


Yilmaz, L.S., Walhout, J.M. (2014) Worms, bacteria

and micronutrients: an elegant model of

our diet. Trends Genet., 30, 496-503.



doi. org/10.1016/j.tig.2014.07.010




Yoo, J., Park, C., Yi, G., Lee, D., Koo, H. (2019) Active

targeting strategies using biological ligands

for nanoparticle drug delivery systems. Cancers,

11(5), pii, E640.


https:// 10.3390/ cancers



. PMID: 31072061

Zwicke, G.L., Mansoori, G.A., Jeffery, C.J. (2012)

Utilizing the folate receptor for active targeting